Results 161 to 170 of about 27,985 (262)

Therapeutic effect of long-acting muscarinic antagonist for treating uncontrolled asthma assessed using impulse oscillometry. [PDF]

Respir Res
Sugawara H, Saito A, Yokoyama S, Chiba H.   +3 more
europepmc   +1 more source

Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.

Respiration, 2021
Lee HW, Kim HJ, Jang EJ, Lee CH.
europepmc   +1 more source

Synthesis of New Cardioselective M2 Muscarinic Receptor Antagonists.

, 2000
Giacomina R. Mandelli, Stefano Maiorana, Patrizia Terni, Giuseppina Lamperti, Maria Luisa Colibretti, Bruno P. Imbimbo   +5 more
openalex   +2 more sources

Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist [PDF]

, 2012
Kazuko Haga, Andrew C. Kruse, Hidetsugu Asada, Takami Yurugi-Kobayashi, Mitsunori Shiroishi, Cheng Zhang, William I. Weis, Tetsuji Okada, Brian K. Kobilka, Tatsuya Haga, Takuya Kobayashi   +10 more
openalex   +1 more source

Exploring the pathophysiology underlying clozapine‐induced enhancement of glutamatergic transmission through L‐glutamate and D‐serine release associated with pannexin1 hemichannels

British Journal of Pharmacology, Volume 182, Issue 19, Page 4710-4728, October 2025.
Abstract Background and purpose Clozapine, an approved antipsychotic for treatment‐resistant schizophrenia (TRS), enhances glutamatergic transmission by increasing exocytosis and non‐exocytosis glutamate release; however, its full action remained to be clarified.
Motohiro Okada, Ruri Okubo, Eishi Motomura   +2 more
wiley   +1 more source

Rationale and Design of an Exploratory, Randomized, Open-Label, Multicenter Clinical Trial to Investigate the Efficacy of Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist on Heart Failure Complicated by Chronic Obstructive Pulmonary Disease (COPD-HF Trial). [PDF]

Circ Rep
Hayashi H, Ito S, Fukuda H, Sata M, Abe Y, Fujimoto K, Fukuda D, Hanajima Y, Horii M, Ikehara N, Inoko M, Izumi C, Izumiya Y, Nakayama T, Sozu T, Toyoda S, Watanabe M, Yokoi M, Kitakaze M.   +18 more
europepmc   +1 more source

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan. [PDF]

Int J Chron Obstruct Pulmon Dis, 2018
Yamada H, Hida N, Hizawa N.
europepmc   +1 more source

Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases

British Journal of Pharmacology, Volume 182, Issue 19, Page 4466-4489, October 2025.
Neurodegenerative disorders are characterised by the chronic progressive degeneration of specific neuronal subtypes, neuroinflammation, myelin damage and synaptic loss. Despite their growing incidence, advancements in effective treatments remain limited, because of lack of knowledge for the aetiology of the diverse pathophysiology to design systematic ...
Ioanna Zota, Theodora Calogeropoulou, Konstantina Chanoumidou, Ioannis Charalampopoulos, Achille Gravanis   +4 more
wiley   +1 more source

The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro. [PDF]

Respir Res
Matera MG, Rinaldi B, Calabrese C, Belardo C, Calzetta L, Cazzola M, Page C.   +6 more
europepmc   +1 more source

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium. [PDF]

Biomed Res Int, 2018
Hamelmann E.
europepmc   +1 more source